Loading stock data…
GKOS
$140.22-3.45 (-2.40%)
Market ClosedLast close May 1
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Glaukos Corporation in the Healthcare sector is trading at $140.22. The stock is currently near its 52-week high of $146.75, remaining 37.5% above its 200-day moving average. Technical signals show overbought RSI of 73 and bullish MACD crossover, explaining why GKOS maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 73) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$140.22
Potential Upside
5%
Whystock Fair Value$147.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$147.58+5.3%
Range$127.00 – $170.00
Fundamentals
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.14%
Volume
Today's trading volume
984,730
Recent News
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out
Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
Glaukos Q1 Earnings Call Highlights
Glaukos (NYSE:GKOS) reported record first-quarter 2026 consolidated net sales of $150.6 million, up 41% on a reported basis and 39% on a constant-currency basis versus the prior-year period, as the company highlighted accelerating momentum in its interventional glaucoma business and the early-stage
Glaukos Corp (GKOS) Q1 2026 Earnings Call Highlights: Record Sales Surge and Raised Guidance
Glaukos Corp (GKOS) reports a 41% increase in net sales and raises full-year guidance, driven by strong performance in its glaucoma and corneal health franchises.
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.